Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2026)

Recursion Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• Quarterly Short term Debt rose 7.9% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 7.9% YoY) and the FY2025 annual result came in at $9.1 million, up 7.91% from the prior year.
• Short term Debt was $9.3 million for Q1 2026 at Recursion Pharmaceuticals, up from $9.1 million in the prior quarter.
• Across five years, Short term Debt topped out at $9.3 million in Q1 2026 and bottomed at $41000.0 in Q4 2023.
• A 4-year average of $7.7 million and a median of $8.6 million in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt surged 20448.78% — and 2026, when it climbed 7.9%.
• Recursion Pharmaceuticals' Short term Debt stood at $41000.0 in 2023, then jumped by 20448.78% to $8.4 million in 2024, then grew by 7.91% to $9.1 million in 2025, then grew by 1.91% to $9.3 million in 2026.
• Business Quant data shows RXRX's Short term Debt at $9.3 million in Q1 2026, $9.1 million in Q4 2025, and $8.9 million in Q3 2025.